EverSource Wealth Advisors’s Aclaris Therapeutics ACRS Stock Holding History

EverSource Wealth Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$101	Sell	19 -458	-96%	-$2.04K	﹤0.01%	4304
2026 Q1	$1.79K	Buy	477 +19	+4%	+$64	﹤0.01%	3681
2025 Q4	$1.38K	Hold	458	–	–	﹤0.01%	3618
2025 Q3	$870	Hold	458	–	–	﹤0.01%	3804
2025 Q2	$650	Buy	+458	New	+$620	﹤0.01%	3832

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

EverSource Wealth Advisors's ACRS Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Aclaris Therapeutics (ACRS) stake by 96% in Q2 2026, selling an estimated $2.04K and leaving 19 shares worth $101. The position accounts for ﹤0.01% of the portfolio, ranked #4304.

EverSource Wealth Advisors first reported a position in ACRS in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.79K in Q1 2026. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

EverSource Wealth Advisors held 19 shares of Aclaris Therapeutics worth $101 as of Q2 2026.
EverSource Wealth Advisors sold 458 Aclaris Therapeutics shares in Q2 2026, an estimated $2.04K.
Aclaris Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4304 holding.
EverSource Wealth Advisors first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 5 quarters since.
EverSource Wealth Advisors's Aclaris Therapeutics position peaked at $1.79K in Q1 2026.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.